{"id":46403,"date":"2022-07-20T22:01:56","date_gmt":"2022-07-20T20:01:56","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/personalis-to-announce-second-quarter-2022-financial-results\/"},"modified":"2022-07-20T22:01:56","modified_gmt":"2022-07-20T20:01:56","slug":"personalis-to-announce-second-quarter-2022-financial-results","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/personalis-to-announce-second-quarter-2022-financial-results\/","title":{"rendered":"Personalis to Announce Second Quarter 2022 Financial Results"},"content":{"rendered":"
\n

MENLO PARK, Calif.–(BUSINESS WIRE)–Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, announced today that it will release its second quarter 2022 financial results on Wednesday, August 3, 2022. In conjunction with the release, Personalis will host a conference call and webcast that day at 2:00 p.m. Pacific Time \/ 5:00 p.m. Eastern Time to discuss its financial results and recent highlights.\n<\/p>\n

<\/a><\/p>\n

\nTo access the live call via telephone, please register in advance using the link here<\/a>. Upon registering, each participant will receive an email confirmation with dial-in numbers and a unique personal PIN that can be used to join the call.\n<\/p>\n

\nThe live webinar of the call may be accessed by visiting the Events section of the company’s website at investors.personalis.com. A replay of the webinar will be available shortly after the conclusion of the call and will be archived on the company’s website.\n<\/p>\n

\nAbout Personalis<\/b>\n<\/p>\n

\nPersonalis, Inc. is a leader in advanced cancer genomics, enabling the next generation of precision cancer therapies and diagnostics. The Personalis NeXT Platform<\/a>\u00ae is designed to adapt to the complex and evolving understanding of cancer, providing its biopharmaceutical customers and clinicians with information on all of the approximately 20,000 human genes, together with the immune system, from a single sample. To enable cancer sequencing, Personalis’ Clinical Laboratory<\/a> was built with a focus on clinical accuracy, quality, big data, scale, and efficiency. The laboratory is GxP-aligned as well as Clinical Laboratory Improvement Amendments of 1988-certified and College of American Pathologists-accredited. For more information, visit the Personalis website<\/a> and follow Personalis on LinkedIn<\/a> and Twitter<\/a>.\n<\/p>\n

Contacts<\/b> <\/p>\n

\nInvestor Relations Contact for Personalis:
\n
Caroline Corner
\n
investors@personalis.com<\/a>
www.westwicke.com<\/a>
415-202-5678\n<\/p>\n

\nMedia Contact for Personalis:
\n
Jennifer Temple
\n
pr@personalis.com<\/a>
www.personalis.com<\/a>
650-752-1300\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

MENLO PARK, Calif.–(BUSINESS WIRE)–Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, announced today that it will release its second quarter 2022 financial results on Wednesday, August 3, 2022. In conjunction with the release, Personalis will host a conference call and webcast that day at 2:00 p.m. Pacific Time \/ 5:00 p.m. … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-46403","6":"format-standard","7":"category-industry"},"yoast_head":"\nPersonalis to Announce Second Quarter 2022 Financial Results - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/personalis-to-announce-second-quarter-2022-financial-results\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Personalis to Announce Second Quarter 2022 Financial Results - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"MENLO PARK, Calif.–(BUSINESS WIRE)–Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, announced today that it will release its second quarter 2022 financial results on Wednesday, August 3, 2022. In conjunction with the release, Personalis will host a conference call and webcast that day at 2:00 p.m. Pacific Time \/ 5:00 p.m. ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/personalis-to-announce-second-quarter-2022-financial-results\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2022-07-20T20:01:56+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20220720005164\/en\/839930\/21\/PersonalisLogo-RGB-no-tagline.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/personalis-to-announce-second-quarter-2022-financial-results\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/personalis-to-announce-second-quarter-2022-financial-results\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Personalis to Announce Second Quarter 2022 Financial Results\",\"datePublished\":\"2022-07-20T20:01:56+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/personalis-to-announce-second-quarter-2022-financial-results\\\/\"},\"wordCount\":302,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/personalis-to-announce-second-quarter-2022-financial-results\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220720005164\\\/en\\\/839930\\\/21\\\/PersonalisLogo-RGB-no-tagline.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/personalis-to-announce-second-quarter-2022-financial-results\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/personalis-to-announce-second-quarter-2022-financial-results\\\/\",\"name\":\"Personalis to Announce Second Quarter 2022 Financial Results - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/personalis-to-announce-second-quarter-2022-financial-results\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/personalis-to-announce-second-quarter-2022-financial-results\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220720005164\\\/en\\\/839930\\\/21\\\/PersonalisLogo-RGB-no-tagline.jpg\",\"datePublished\":\"2022-07-20T20:01:56+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/personalis-to-announce-second-quarter-2022-financial-results\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/personalis-to-announce-second-quarter-2022-financial-results\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/personalis-to-announce-second-quarter-2022-financial-results\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220720005164\\\/en\\\/839930\\\/21\\\/PersonalisLogo-RGB-no-tagline.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220720005164\\\/en\\\/839930\\\/21\\\/PersonalisLogo-RGB-no-tagline.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/personalis-to-announce-second-quarter-2022-financial-results\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Personalis to Announce Second Quarter 2022 Financial Results\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Personalis to Announce Second Quarter 2022 Financial Results - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/personalis-to-announce-second-quarter-2022-financial-results\/","og_locale":"en_US","og_type":"article","og_title":"Personalis to Announce Second Quarter 2022 Financial Results - Pharma Trend","og_description":"MENLO PARK, Calif.–(BUSINESS WIRE)–Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, announced today that it will release its second quarter 2022 financial results on Wednesday, August 3, 2022. In conjunction with the release, Personalis will host a conference call and webcast that day at 2:00 p.m. Pacific Time \/ 5:00 p.m. ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/personalis-to-announce-second-quarter-2022-financial-results\/","og_site_name":"Pharma Trend","article_published_time":"2022-07-20T20:01:56+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20220720005164\/en\/839930\/21\/PersonalisLogo-RGB-no-tagline.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/personalis-to-announce-second-quarter-2022-financial-results\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/personalis-to-announce-second-quarter-2022-financial-results\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Personalis to Announce Second Quarter 2022 Financial Results","datePublished":"2022-07-20T20:01:56+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/personalis-to-announce-second-quarter-2022-financial-results\/"},"wordCount":302,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/personalis-to-announce-second-quarter-2022-financial-results\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220720005164\/en\/839930\/21\/PersonalisLogo-RGB-no-tagline.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/personalis-to-announce-second-quarter-2022-financial-results\/","url":"https:\/\/pharma-trend.com\/en\/personalis-to-announce-second-quarter-2022-financial-results\/","name":"Personalis to Announce Second Quarter 2022 Financial Results - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/personalis-to-announce-second-quarter-2022-financial-results\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/personalis-to-announce-second-quarter-2022-financial-results\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220720005164\/en\/839930\/21\/PersonalisLogo-RGB-no-tagline.jpg","datePublished":"2022-07-20T20:01:56+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/personalis-to-announce-second-quarter-2022-financial-results\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/personalis-to-announce-second-quarter-2022-financial-results\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/personalis-to-announce-second-quarter-2022-financial-results\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20220720005164\/en\/839930\/21\/PersonalisLogo-RGB-no-tagline.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20220720005164\/en\/839930\/21\/PersonalisLogo-RGB-no-tagline.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/personalis-to-announce-second-quarter-2022-financial-results\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Personalis to Announce Second Quarter 2022 Financial Results"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/46403","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=46403"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/46403\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=46403"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=46403"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=46403"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}